Roche en route to first continuous delivery treatment for nAMD in Europe
CE mark for Contivue platform supports its ambitions for Susvimo in age-related macular degeneration (AMD).
List view / Grid view
CE mark for Contivue platform supports its ambitions for Susvimo in age-related macular degeneration (AMD).
The ocular injection, now granted its third FDA approval, offers a more convenient treatment option for patients with vision loss.
The monoclonal antibody treatment is now approved in the US for both diabetic macular oedema and wet, or neovascular age-related macular degeneration.
The Committee for Medicinal Products for Human Use (CHMP) recommended two new medicines for approval in its May meeting, including a neurosteroid for epileptic seizures.